Merinfec

Meropenem, the active ingredient in Merinfec, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous injection. It provides broad‑spectrum antibacterial activity and is used to treat severe, hospital‑acquired infections in adult and pediatric patients requiring parenteral therapy.

GNH USA supplies Merinfec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Our global logistics network ensures timely delivery across multiple regions.

Meropenem is employed for serious bacterial infections affecting various organ systems, particularly in hospital settings.

- Complicated intra‑abdominal infection: provides broad coverage against aerobic and anaerobic pathogens, facilitating infection control after surgery. - Hospital‑acquired pneumonia, including ventilator‑associated pneumonia: achieves rapid bacterial eradication in the lower respiratory tract. - Complicated urinary tract infection: eliminates resistant gram‑negative organisms causing pyelonephritis and cystitis. - Bacterial meningitis: penetrates the cerebrospinal fluid to treat susceptible pathogens in acute meningitis.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset occurring in many patients. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional emesis during therapy. - Headache: transient cranial discomfort. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile‑associated colitis: severe diarrhea due to intestinal flora disruption. - Anaphylaxis: acute hypersensitivity reaction with respiratory and cardiovascular compromise. - Severe neutropenia: marked reduction in neutrophil count. - Renal toxicity: acute kidney injury in susceptible individuals. - Thrombocytopenia: low platelet counts leading to bleeding risk.

When using Merinfec, clinicians should observe several precautionary measures to minimize risks.

- Renal impairment: adjust dose based on creatinine clearance to avoid accumulation. - Seizure risk: monitor patients with a history of epilepsy or CNS disorders for neurotoxicity. - Hypersensitivity: avoid in individuals with known allergy to carbapenems or β‑lactam antibiotics. - Concomitant valproic acid: discontinue or substitute as meropenem can lower valproate levels and precipitate seizures. - Combination therapy: use caution when co‑administered with other nephrotoxic agents such as aminoglycosides. - Pregnancy and lactation: prescribe only if benefits outweigh potential risks, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum valproate concentrations, increasing seizure risk. - Probenecid: may raise meropenem plasma levels, heightening toxicity potential. - Renal tubular secretion inhibitors (e.g., cimetidine): can increase meropenem exposure and renal adverse effects.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function closely. - Loop diuretics: may enhance ototoxic risk when combined with other ototoxic agents. - Other β‑lactam antibiotics: potential antagonism; assess need for combination therapy. - Anticoagulants (warfarin): monitor INR as infection resolution may alter coagulation status.